Definitive Contract 75D30122C13720
Award Date
5/16/22
Potential Completion Date
5/14/25
Potential Value
$82M
Federal Agency
CDC Pittsburgh
Awardee
Helix Opco LLC
Ultimate Awardee
Not listed
NAICS Category
621511 - Medical Laboratories
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Mateo, CA 94401, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
23
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
Helix Opco, LLC was awarded a $10.88 million firm fixed price definitive contract by the Centers for Disease Control and Prevention (CDC) on September 17, 2021 to provide genomic sequencing services. The contract has a period of performance through May 14, 2022 and was issued without a set-aside designation. As a for-profit limited liability company located in San Mateo, California, Helix Opco will deliver the sequencing services from its place of performance in the same city. No major...
This is a $5,000,000.00 firm fixed price contract awarded by the Centers for Disease Control and Prevention (CDC) to Helix Opco LLC, a for-profit limited liability company based in San Mateo, California. The contract was awarded on September 30, 2022 under the CDC's "FY22 BAA - APPLIED RESEARCH TO ADDRESS EMERGING PUBLIC HEALTH PRIORITIES" solicitation, with a period of performance ending on September 29, 2023. The contract does not have a set-aside designation. Helix Opco has...
This is a $2,190,000.00 firm fixed price definitive contract awarded by the Centers for Disease Control and Prevention (CDC) to Helix Opco LLC, a for-profit limited liability company located in San Mateo, California. The contract is for FY22 BAA - TOPIC 7 - IDENTIFYING VIRAL AND HOST GENETIC DETERMINANTS OF VACCINE EFFICACY and has a period of performance ending on September 29, 2023. No set-aside designation was used. Based on Helix Opco's prior contract history, the work under this award...
The Centers for Disease Control and Prevention awarded a $600,000 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The contract calls for SARS-COV-2 SPHERES baseline genomic sequencing in support of the CDC's coronavirus COVID-19 programs. Performance will take place in San Diego through March 2021. As the leading public health agency in the U.S., the CDC routinely sequences virus genomes to track disease spread and evolution, providing genomic surveillance...
The Centers for Disease Control and Prevention awarded a $3.975 million firm fixed price definitive contract to Illumina, Inc. of San Diego, California. The contract is for SARS-COV-2 SPHERES Baseline Genomic Sequencing to support the Department of Health and Human Services and CDC's efforts responding to the Coronavirus Disease 2019 (COVID-19) pandemic. Under this contract, Illumina will provide genomic sequencing and data analysis services to establish a baseline of SARS-CoV-2 virus genomes...
The Centers for Disease Control and Prevention (CDC) awarded a $39.9 million firm fixed price definitive contract to Aegis Sciences Corporation for COVID-19 genome sequencing services. As the prime contractor, Aegis Sciences Corporation will perform the sequencing work out of its Nashville, Tennessee laboratory. The one year contract is intended to support the CDC's ongoing efforts to track genetic variations of the SARS-CoV-2 virus through genomic surveillance. No subcontractors or set aside...
The Centers for Disease Control and Prevention (CDC) awarded a $74.4 million Definitive Contract to Quest Diagnostics Incorporated for COVID-19 Genomic Sequencing services. The three-year Firm Fixed Price contract runs from May 16, 2022 through May 14, 2025 and will be performed in Secaucus, New Jersey. Quest Diagnostics will provide genomic sequencing to support CDC's efforts to track SARS-CoV-2 virus variants as part of the United States COVID-19 genomic surveillance program. No...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $2.5 million definitive contract to the Scripps Research Institute for genomic sequencing of SARS-CoV-2 to investigate local and cross-border emergence and spread. This contract was awarded under the Centers for Disease Control COVID-19 Broad Agency Announcement, which sought white papers related to developing strategies for protecting communities from COVID-19, including examining the virus's...
The Department of Health and Human Services Centers for Disease Control and Prevention (CDC) has awarded a $170,641.14 firm fixed price purchase order contract to Illumina, Inc., a manufacturer of genomic sequencing systems and reagents. The contract is for the delivery of genomic sequencing kits, with a period of performance through August 28, 2024. Illumina has a history of providing sequencing instruments, reagents, and services to various federal agencies, including the National...
This firm fixed-price purchase order contract was awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents, to facilitate the relocation of equipment to accommodate COVID-19 (CORVD) operations. The $20,092.00 contract has an ultimate completion date of August 1, 2024. Illumina has a history of providing sequencing systems and associated services to support genomic research and diagnostics across various...